Sign up to save your podcasts
Or
Share Retatrutide Weight Loss: How Much At Each Dose
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Retatrutide Weight Loss: How Much At Each Dose
https://www.otplinks.com
0:00 Welcome & today’s focus: Retatrutide and “chasing the biggest number”
1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping
2:10 How Dave first heard about retatrutide (work trip, early phase 1 data)
3:35 Flashback clip: early excitement about retatrutide phase 3 trials
4:40 Why this new retatrutide data feels different for obesity medicine
5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population
7:00 Headline results: 28.7% average weight loss, surgery-level efficacy
8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates)
11:05 What “efficacy estimate” really means (race-track analogy)
13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal
15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ
18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences)
21:02 Why the lower doses matter & who actually needs 30% weight loss
24:15 From “just make the scale go down” to quality of weight loss & body composition
28:05 Future focus: health, longevity, and peptides beyond hitting goal weight
30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor”
34:38 How retatrutide changes the next decade of obesity treatment conversations
37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook
40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review
45:20 Why small-molecule oral GLP-1s aren’t the same as injectable peptides
48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned
51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA
54:28 How the bill undermines personalization while ignoring real safety tools
57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting
59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors
1:02:05 Call to action: petition at otplinks.com & why patient voices matter
1:05:10 Change.org impact, media attention & centering the patient perspective
1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
View all episodes
By Bleav, Dave Knapp Founder of On The Pen
4.9
351351 ratings
https://www.otplinks.com
0:00 Welcome & today’s focus: Retatrutide and “chasing the biggest number”
1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping
2:10 How Dave first heard about retatrutide (work trip, early phase 1 data)
3:35 Flashback clip: early excitement about retatrutide phase 3 trials
4:40 Why this new retatrutide data feels different for obesity medicine
5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population
7:00 Headline results: 28.7% average weight loss, surgery-level efficacy
8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates)
11:05 What “efficacy estimate” really means (race-track analogy)
13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal
15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ
18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences)
21:02 Why the lower doses matter & who actually needs 30% weight loss
24:15 From “just make the scale go down” to quality of weight loss & body composition
28:05 Future focus: health, longevity, and peptides beyond hitting goal weight
30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor”
34:38 How retatrutide changes the next decade of obesity treatment conversations
37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook
40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review
45:20 Why small-molecule oral GLP-1s aren’t the same as injectable peptides
48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned
51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA
54:28 How the bill undermines personalization while ignoring real safety tools
57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting
59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors
1:02:05 Call to action: petition at otplinks.com & why patient voices matter
1:05:10 Change.org impact, media attention & centering the patient perspective
1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More shows like On The Pen With Dave Knapp
View all
The Hormone Solution with Karen Martel
333 Listeners
Everyday Wellness: Midlife Hormones, Menopause, and Science for Women 35+
141 Listeners
The Holistic GLP-1 Podcast with Elizabeth McGann
48 Listeners
The Hunter Williams Podcast
106 Listeners
The Dr. Tyna Show
1,643 Listeners
Docs Who Lift
388 Listeners
The Obesity Guide with Matthea Rentea MD
244 Listeners
The Plus SideZ: A Guide to GLP-1 & Metabolic Health
217 Listeners
Game-Changing Health
36 Listeners
The Peptide Podcast
85 Listeners
Fat Science
168 Listeners
West Wellness & Longevity
36 Listeners
GLP-1 Hub: Support, Community, and Weight Loss
14 Listeners
GLP-1 Tribe
43 Listeners
Today's discussion on unraveling BPC 157 Peptide
22 Listeners